These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29145460)

  • 1. TRAIL attenuates RANKL-mediated osteoblastic signalling in vascular cell mono-culture and co-culture models.
    Harper E; Rochfort KD; Forde H; Davenport C; Smith D; Cummins PM
    PLoS One; 2017; 12(11):e0188192. PubMed ID: 29145460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the non-canonical NF-κB/p52 pathway in vascular endothelial cells by RANKL elicits pro-calcific signalling in co-cultured smooth muscle cells.
    Harper E; Rochfort KD; Forde H; Davenport C; Smith D; Cummins PM
    Cell Signal; 2018 Jul; 47():142-150. PubMed ID: 29678621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANKL promotes osteoblastic activity in vascular smooth muscle cells by upregulating endothelial BMP-2 release.
    Davenport C; Harper E; Forde H; Rochfort KD; Murphy RP; Smith D; Cummins PM
    Int J Biochem Cell Biol; 2016 Aug; 77(Pt A):171-180. PubMed ID: 27339040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL.
    Harper E; Forde H; Davenport C; Rochfort KD; Smith D; Cummins PM
    Vascul Pharmacol; 2016 Jul; 82():30-40. PubMed ID: 26924459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL treatment of vascular endothelial cells leading to paracrine pro-calcific signaling involves ROS production.
    Harper E; Rochfort KD; Smith D; Cummins PM
    Mol Cell Biochem; 2020 Jan; 464(1-2):111-117. PubMed ID: 31724123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain.
    Davenport C; Harper E; Rochfort KD; Forde H; Smith D; Cummins PM
    J Vasc Res; 2018; 55(2):111-123. PubMed ID: 29635231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells.
    Olesen M; Skov V; Mechta M; Mumm BH; Rasmussen LM
    Mol Cell Endocrinol; 2012 Oct; 362(1-2):149-56. PubMed ID: 22698523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
    Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
    J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification.
    Osako MK; Nakagami H; Koibuchi N; Shimizu H; Nakagami F; Koriyama H; Shimamura M; Miyake T; Rakugi H; Morishita R
    Circ Res; 2010 Aug; 107(4):466-75. PubMed ID: 20595654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
    Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
    Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification.
    Tintut Y; Demer L
    J Investig Med; 2006 Nov; 54(7):395-401. PubMed ID: 17169261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infantile haemangioma expresses tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, osteoprotegerin and receptor activator for nuclear factor кB ligand (RANKL).
    Vishvanath A; Itinteang T; Tan ST; Day DJ
    Histopathology; 2011 Sep; 59(3):397-406. PubMed ID: 22034880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy.
    Ndip A; Williams A; Jude EB; Serracino-Inglott F; Richardson S; Smyth JV; Boulton AJ; Alexander MY
    Diabetes; 2011 Aug; 60(8):2187-96. PubMed ID: 21659498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implicating Receptor Activator of NF-κB (RANK)/RANK Ligand Signalling in Microglial Responses to Toll-Like Receptor Stimuli.
    Kichev A; Eede P; Gressens P; Thornton C; Hagberg H
    Dev Neurosci; 2017; 39(1-4):192-206. PubMed ID: 28402971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
    J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.
    McGonigle JS; Giachelli CM; Scatena M
    Angiogenesis; 2009; 12(1):35-46. PubMed ID: 19105036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity.
    Venuraju SM; Yerramasu A; Corder R; Lahiri A
    J Am Coll Cardiol; 2010 May; 55(19):2049-61. PubMed ID: 20447527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
    Nyambo R; Cross N; Lippitt J; Holen I; Bryden G; Hamdy FC; Eaton CL
    J Bone Miner Res; 2004 Oct; 19(10):1712-21. PubMed ID: 15355567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.